Want to see AU:AT1 full AI Analyst Report?
AT1 Stock Chart & Stats
AU$0.02
<AU$0.01(5.88%)
At close: 4:00 PM EDT
AU$0.02
<AU$0.01(5.88%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.05
Previous CloseN/A
Volume86.61K
Average Volume (3M)498.10K
Market Cap
AU$16.24M
Enterprise ValueAU$11.18
Total Cash (Recent Filing)AU$3.71M
Total Debt (Recent Filing)AU$373.08K
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding902,432,860
10 Day Avg. Volume498,356
30 Day Avg. Volume498,097
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.82
Price to Sales (P/S)2.64
P/FCF Ratio-4.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$31.96M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe strong FY2026 revenue rebound indicates renewed demand for Atomo’s diagnostic device platforms and supports a more favorable growth trajectory. If this momentum continues through partner orders and test volumes, it can improve operating leverage and strengthen the company’s commercial position over the next several quarters.
Low Financial LeverageMinimal leverage reduces refinancing pressure and limits interest-related demands on operating cash flow. This gives Atomo greater flexibility to fund product development, commercialisation work, and customer programs while avoiding the balance-sheet strain that can accompany expansion by borrowing.
Improving Loss ProfileThe narrower net loss and reduced cash burn suggest that cost control and operating execution improved from earlier periods. Although profitability has not been achieved, continued progress could extend the company’s funding runway and create a clearer path toward eventual operating break-even.
Bears Say
Negative Gross MarginA negative gross margin means recent product revenue did not cover the associated cost base, undermining the economics of the current sales mix. Unless pricing, production costs, or inventory-related impacts improve, revenue growth may not translate into sustainable earnings or stronger cash generation.
Persistent Cash ConsumptionConsistently negative operating and free cash flow shows that Atomo has not yet demonstrated self-funded operations. Even with recent improvement, ongoing cash consumption can require additional funding and may constrain investment in platform development, customer integration, and commercial scale-up.
Eroding Equity BaseA declining equity base reflects the cumulative impact of sustained losses and reduces the financial cushion available to absorb further underperformance. If losses continue, Atomo may have less flexibility to support growth internally and greater reliance on future capital or operating improvement.
Atomo Diagnostics Ltd. News
AT1 FAQ
What was Atomo Diagnostics Ltd.’s price range in the past 12 months?
Atomo Diagnostics Ltd. lowest share price was AU$0.02 and its highest was AU$0.05 in the past 12 months.
What is Atomo Diagnostics Ltd.’s market cap?
Atomo Diagnostics Ltd.’s market cap is AU$16.24M.
When is Atomo Diagnostics Ltd.’s upcoming earnings report date?
Atomo Diagnostics Ltd.’s upcoming earnings report date is Feb 24, 2027 which is in 158 days.
How were Atomo Diagnostics Ltd.’s earnings last quarter?
Atomo Diagnostics Ltd. released its earnings results on Aug 30, 2026. The company reported -AU$0.002 earnings per share for the quarter.
Is Atomo Diagnostics Ltd. overvalued?
According to Wall Street analysts Atomo Diagnostics Ltd.’s price is currently Overvalued.
Does Atomo Diagnostics Ltd. pay dividends?
Atomo Diagnostics Ltd. does not currently pay dividends.
What is Atomo Diagnostics Ltd.’s EPS estimate?
Atomo Diagnostics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atomo Diagnostics Ltd. have?
Atomo Diagnostics Ltd. has 902,432,860 shares outstanding.
What happened to Atomo Diagnostics Ltd.’s price movement after its last earnings report?
Atomo Diagnostics Ltd. reported an EPS of -AU$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Atomo Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:AT1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atomo Diagnostics Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Atomo Diagnostics Ltd.
Established in 2010 and based in Leichhardt, Australia, Atomo Diagnostics Limited is a global enterprise focused on the innovation and commercialization of medical devices. The company provides swift-result diagnostic tools designed for various applications, including COVID-19 detection, HIV screening, pregnancy confirmation, and assessing respiratory conditions.
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―